Elicio Therapeutics, Inc. (ELTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on September 17, 2025, by Elicio Therapeutics, Inc., a Delaware corporation. The filing discloses material clinical trial data regarding the Company's lead candidate, ELI-002 7P, a lymph node-targeted amphiphile therapeutic cancer vaccine. The report focuses on immunogenicity results from the ongoing Phase 2 AMPLIFY-7P trial.
Key Financial Metrics
This filing is a non-financial disclosure under Regulation FD and Item 8.01. It does not contain revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Clinical Data
The Company reported robust mKRAS-specific T cell responses in the Phase 2 AMPLIFY-7P trial, showing significant improvements and consistency compared to prior Phase 1 data:
- Overall Response Rate: 99% (89 of 90) of evaluable patients in Phase 2 generated robust mKRAS-specific T cell responses, compared to 100% (12 of 12) in the Phase 1 MRD+ only cohort.
- Fold Change Increase: The average increase over baseline was 145.3x in Phase 2, compared to 71.1x in Phase 1. The median increase was 44.3x in Phase 2 versus 18.5x in Phase 1.
- CD4 and CD8 Response: 85% of Phase 2 patients exhibited combined CD4 and CD8 responses, an increase from 75% in the Phase 1 trial.
- Antigen Specificity: 67.4% of Phase 2 patients responded to all seven mKRAS antigens (up from 50% in Phase 1). Response to patient-specific tumor mKRAS antigens was 87.6% (up from 83.3% in Phase 1).
- Overall Antigen Response: Positive T cell responses were observed for 85.7% of vaccine antigens in Phase 2, compared to 66.7% in Phase 1.
The data indicates that 80% of Phase 2 patients exceeded the ~9x baseline threshold previously correlated with clinical activity in Phase 1 studies.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance or updated clinical trial timelines. Management commentary emphasizes the consistency of immunogenicity data between Phase 1 and Phase 2 trials, suggesting the vaccine's mechanism of action is validated across patient populations (MRD+ and MRD-). The filing notes that the correlation between the observed T cell response magnitude and clinical activity in the Phase 2 trial is "To Be Determined" (TBD), though 80% of patients exceeded the historical threshold for activity.
Investor Verification Checklist
- Verify the full text of the Press Release (Exhibit 99.1) and Corporate Presentation (Exhibit 99.2) for detailed statistical analysis and patient demographics.
- Confirm the definition of "evaluable patients" and the specific assay methods used for T cell response measurement.
- Monitor future filings for the determination of clinical activity correlation (TBD) in the Phase 2 trial.
- Review the Company's cash position in the most recent 10-Q or 10-K, as this 8-K contains no liquidity data.